TMHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TMHC is sitting just above near-term support (60.42) but the short-term trend is still weakening (bearish/expanding MACD). With no Intellectia buy signals today and recent quarter fundamentals (Q3 2025) showing YoY declines in revenue, EPS, net income, and gross margin, the odds favor a choppy/low-conviction entry at the current 60.95. For an impatient buyer, this setup lacks an immediate edge unless price reclaims the pivot (62.58) with improving momentum.
Price/levels: Post-market 60.95, below the pivot (62.576) and close to S1 (60.42); a clean break below S1 opens room toward S2 (59.088). Resistance overhead at 62.58 then 64.73. Momentum: MACD histogram -0.279 and negatively expanding = downside momentum increasing. RSI(6) 35.1 = weak/near-oversold but not yet a clear reversal signal. Moving averages are converging = consolidation after weakness, but without a confirmed trend turn. Pattern-based projection provided: ~7.48% upside over the next month, but near-term (next week) is slightly negative, implying any upside likely needs a base/bounce confirmation first.
Intellectia Proprietary Trading Signals
and RSI near-oversold. Next earnings (QDEC
on 2026-02-11 pre-market can act as a catalyst if margins/orders surprise positively.
Macro/sector headwinds cited by analysts: affordability, rates, policy/tariff risks, and expected volatility for homebuilders into early
No supportive news flow in the last week to change the narrative. Recent RBC price target cut to $62 (from $
signals tempered near-term enthusiasm and sits close to the current price, limiting immediate perceived upside from that shop.
Latest reported quarter: 2025/Q3. Revenue 2.096B (-1.18% YoY), Net income 201.4M (-19.78% YoY), EPS 2.01 (-15.19% YoY), Gross margin 23.09 (-7.79% YoY). Trend read: profitability and margins are compressing faster than revenue, which typically reduces confidence in near-term multiple expansion for a homebuilder unless forward demand/margins stabilize.
Recent trend: Price targets have mostly been supportive but with mixed near-term caution. RBC (2026-01-09) lowered PT to $62 (from $68) but kept Outperform; JPM (2025-12-04) raised PT to $76 and maintained Overweight; Barclays (2025-12-08) raised PT to $71 and maintained Overweight; Citizens (2026-01-07) initiated Outperform with a notably bullish $95 PT. Wall Street pros: perceived valuation discount vs peers, expectation of stabilizing gross margins, and resilient move-up/active-adult buyer mix. Wall Street cons: affordability/rates pressure, policy/tariff uncertainty, volatile 2026 setup for homebuilders, and risk of weaker builder fundamentals. Influential/political trading: No recent congress trading data available; hedge fund and insider trends are neutral (no significant recent buying/selling signals).
